Novelion Therapeutics

Novelion Therapeutics is a biopharmaceutical company that establishes new standards of care for individuals with rare diseases. The company's portfolio includes MYALEPT and JUXTAPID, and it is developing Uridine Triacetate for the treatment of hereditary retinal diseases caused by underlying mutations in the RPE65 or LRAT genes.